Compare BEEM & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | VTGN |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | 276 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 24.1M |
| IPO Year | N/A | 2014 |
| Metric | BEEM | VTGN |
|---|---|---|
| Price | $1.91 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $3.50 | $0.90 |
| AVG Volume (30 Days) | 626.8K | ★ 648.3K |
| Earning Date | 04-09-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | $40.48 | $124.49 |
| Revenue Next Year | $32.17 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $0.43 |
| 52 Week High | $4.04 | $5.14 |
| Indicator | BEEM | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 48.76 |
| Support Level | $1.59 | $0.57 |
| Resistance Level | $1.99 | $0.60 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 78.45 | 56.86 |
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.